PDK1 and pancreatic neoplasm: In this study, two novel dual inhibitors targeting PDK1 and Aurora kinase A have been tested in a panel of pancreatic cancer cell lines and compared to non-malignant cells to check the effect of their activity on PI3K and Aurora kinase A pathways, and their potential as anticancer agents.